modelL01FF04
Extends from Pharmacokinetic.Models.PK_2C.
Information
| name: | Avelumab | |
| ATC code: | L01FF04 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 800 | mg |
| volume of distribution: | 4.72 | L |
| clearance: | 0.59 | L/day |
| other parameters in model implementation | ||
Avelumab is a fully human monoclonal antibody of the IgG1 isotype that targets programmed death-ligand 1 (PD-L1). It is approved for the treatment of metastatic Merkel cell carcinoma and advanced or metastatic urothelial carcinoma. It functions as an immune checkpoint inhibitor, enhancing T-cell mediated immune response against cancer cells.
Pharmacokinetics
Pharmacokinetics in adult cancer patients following intravenous administration; parameters are based on population PK analysis in patients with advanced solid tumors, median age 64 years (range 20–89).
References
Vugmeyster, Y, et al., & Khandelwal, A (2022). Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors. Clinical pharmacokinetics 61(7) 985–995. DOI:10.1007/s40262-022-01111-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35484319
Masters, JC, et al., & Brar, S (2022). Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma. CPT: pharmacometrics & systems pharmacology 11(4) 458–468. DOI:10.1002/psp4.12771 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35166465
Heery, CR, et al., & Gulley, JL (2017). Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. The Lancet. Oncology 18(5) 587–598. DOI:10.1016/S1470-2045(17)30239-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28373007
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)